XML 44 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 11 - Stockholders' Equity
12 Months Ended
Dec. 31, 2017
Notes to Financial Statements  
Shareholders' Equity and Share-based Payments [Text Block]
NOTE
1
1
– Stockholders’ e
quity
 
2001
Non-Qualified Stock Option Plan
 
In
November 2006,
the Company registered a non-qualified stock option plan that the shareholders had approved in
July 2001,
covering key employees, officers, directors and other persons that
may
be considered as service providers to the Company. Options
were awarded by the Board of Directors or by a committee appointed by the Board. Under the plan, an aggregate
of
300,000
shares of Company common stock,
$.01
par value, were reserved for issuance or transfer upon the exercise of options which were granted. Unless otherwise provided in the option agreement, options granted under the plan would vest over a
four
year period commencing
one
year from the anniversary date of the grant. The stock option plan expired on
July 22, 2011.
 
2007
Share Incentive Plan
 
On
December 12, 2007,
shareholders approved the Company
’s
2007
Share Incentive Plan (“Incentive Plan”), in connection therewith,
750,000
shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that
may
be granted under the Share
 Incentive Plan through
December 12, 2017.
In
2017,
75,324
shares of stock were granted and issued to directors and key employees, additionally, options were granted to
three
key employees for
140,000
shares of the Company
’s common stock. In
2016,
42,320
shares of stock were granted and issued to directors and key employees. The Plan expired in
December, 2017.
 
2016
Share Incentive Plan
 
On
December 9, 2016,
shareholders approved the Company
’s
2016
Share Incentive Plan (
“2016
Incentive Plan”), in connection therewith
750,000
shares of the Company’s common stock are
 
reserved for issuance pursuant to options or restricted stock that
may
be granted under the
2016
Incentive Plan through
December 9, 2026.
No
shares have been issued yet from this Plan.
 
The purchase price of the common stock under each option plan shall be determined by the Committee, provided, however, that such purchase price shall
not
be less than the fair market
value of the shares on the date such option is granted. The stock options generally expire
seven
to
ten
years after the date of grant. The Company recorded stock-based compensation of
$933,000
and
$776,000
for the years ended
December 31, 2017
and
2016,
respectively.
 
A summary of the stock option activity related to the
2001
Stock Option Plans and the
2007
Share Incentive Plan for the period from
January 1,
201
6
through
December 31, 2017
is as follows:
 
2001
Non-Qualified Stock Option Plan
 
   
Beginning
   
Granted
   
Exercised
   
Canceled
   
Ending
         
   
Balance
   
During
   
During
   
During
   
Balance
         
   
Outstanding
   
Period
   
Period
   
Period
   
Outstanding
   
Exercisable
 
                                                 
Year ended December 31, 201
6
                                               
Number of shares
   
124,480
     
-0-
     
64,750
     
-0-
     
59,730
     
59,730
 
Weighted average exercise price Per share
  $
4.57
     
-0-
     
4.62
     
-0-
    $
4.51
    $
4.51
 
Year ended December 31, 201
7
                                               
Number of shares
   
59,730
     
-0-
     
36,800
     
-0-
     
22,930
     
22,930
 
Weighted average exercise price Per share
  $
4.51
     
-0-
     
3.97
     
-0-
    $
5.36
    $
5.36
 
 
2007
Share Incentive Plan
 
   
Beginning
   
Granted
   
Exercised
   
Canceled
   
Ending
         
   
Balance
   
During
   
During
   
During
   
Balance
         
   
Outstanding
   
Period
   
Period
   
Period
   
Outstanding
   
Exercisable
 
                                                 
Year ended December 31, 201
6
                                               
Number of shares
   
100,000
     
125,000
     
-0-
     
-0-
     
225,000
     
65,000
 
Weighted average exercise price Per share
  $
11.17
     
8.04
     
-0-
     
-0-
    $
9.43
    $
9.97
 
Year ended December 31, 201
7
                                               
Number of shares
   
225,000
     
140,000
     
-0-
     
-0-
     
365,000
     
185,000
 
Weighted average exercise price Per share
  $
9.43
     
10.82
     
-0-
     
-0-
    $
12.35
    $
13.76
 
 
 
The Company has
387,930
of outstanding stock options under the
two
plans at
December 31, 2017.
 
The following table summarizes information about the outstanding and exercisable options at
December 31,
201
7.
 
           
Options Outstanding
                   
Options Exercisable
         
                   
Weighted
   
Weighted
                   
Weighted
         
                   
Average
   
Average
                   
Average
         
Exercis
e
   
Number
   
Remaining
   
Exercise
   
Intrinsic
   
Number
   
Exercise
   
Intrinsic
 
Price Range
   
Outstanding
   
Contractual
   
Price
   
Value
   
Exercisable
   
Price
   
Value
 
 
$4.00
-
7.00
     
15,930
     
2.00
    $
4.25
    $
117,404
     
15,930
    $
4.25
    $
117,404
 
 
$7.00
-
10.00
     
7,000
     
3.00
    $
7.90
    $
26,040
     
9,800
    $
7.90
    $
26,040
 
 
$10.01
-
12.00
     
240,000
     
8.3
    $
10.96
    $
158,400
     
65,000
    $
11.17
    $
27,000
 
 
$12.01
-
15.00
     
125,000
     
4.5
    $
15.00
    $
0
     
125,000
    $
15.00
    $
0
 
 
The intrinsic value of the
34,000
options exercised during the year ended
December 31, 2017
was
$256,000.
The intrinsic value of the
100,000
options exercised during the year ended
December 31, 2016
was
$203,000.
 
Restricted Stock Awards
 
The following table summarizes restricted stock awards for the year
s ended
December 31, 2017
and
2016:
 
           
Weighted
 
   
Shares of
   
Average Grant
 
   
Restricted
   
Date Fair
 
   
Stock
   
Value
 
Unvested
outstanding at January 1, 2016
   
4,000
    $
10.97
 
                 
Granted
   
17,524
    $
8.45
 
Vested
   
(21,524
)   $
12.84
 
Forfeited/Cancelled
   
-
     
 
 
                 
Unvested outstanding at December 31, 201
6
   
0
    $
0
 
                 
Granted
   
9,300
    $
9.70
 
Vested
   
(9,300
)   $
9.70
 
Forfeited/Cancelled
   
-
     
 
 
                 
Unvested outstanding at December 31, 201
7
   
-0-
    $
 
 
 
The total fair value of shares of restricted stock awards vested for the years ended
December 31,
201
7
and
2016
was approximately
$90,000
and
$276,000
respectively.
 
The fair value of the outstanding restricted stock awards will be recorded as stock compensation expense over the vesting period.
 
Restricted Stock Units
 
The following table summarizes restricted stock units for the year
s ended
December 31, 2017
and
December 31, 2016:
 
           
Weighted
 
   
Shares of
   
Average Grant
 
   
Restricted
   
Date Fair
 
   
Stock Units
   
Value
 
Unvested outstanding at January 1, 201
6
   
94,580
    $
12.55
 
                 
Granted
   
60,400
    $
8.56
 
Vested
   
(33,890
)   $
12.43
 
Forfeited/Cancelled
   
(7,000
)   $
11.68
 
                 
Unvested outstanding at December 31, 201
6
   
114,090
    $
10.47
 
                 
Granted
   
39,720
    $
10.88
 
Vested
   
(58,776
)   $
10.83
 
Forfeited/Cancelled
   
(125
)   $
14.61
 
                 
Unvested outstanding at December 31, 201
7
   
94,909
    $
10.43
 
 
The total fair value of vested restricted stock units was $
637,000
and
$421,000
respectively for the years ended
December 31, 2017
and
2016.
 
The fair value of the outstanding restricted stock units will be recorded as stock compensation expense over the vesting period. As of
December 31,
201
7,
there was
$990,000
of total unrecognized compensation costs related to restricted stock units, which is expected to be recognized over a weighted-average period of
1.58
years.
 
During the
years ended
December 31, 2017
and
2016,
the Company recorded into selling and general administrative expense approximately
$933,000
and
$776,000
for the cost of employee and director services received in exchange for equity instruments based on the grant-date fair value of those instruments in accordance with the provisions of ASC
718.